Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulphate under solid state stress conditions

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 3, 2010, Pages 332-344

  Raijada, Dhara K ^a   Prasad, Bhagwat ^a   Paudel, Amrit ^a   Shah, Ravi P ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Clopidogrel bisulphate; LC MS TOF; LC MSn; Solid state degradation; Stress studies

Indexed keywords

CLOPIDOGREL;

ARTICLE; CONTROLLED STUDY; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUTION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLID STATE; STRESS; TEMPERATURE; TIME OF FLIGHT MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; DOSAGE FORMS; DRUG STABILITY; HOT TEMPERATURE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; LIGHT; MASS SPECTROMETRY; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PHOTOLYSIS; PLATELET AGGREGATION INHIBITORS; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL; TICLOPIDINE; TIME FACTORS; X-RAY DIFFRACTION;

EID: 77649342701     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.05.001     Document Type: Article

References (24)

1. Newman A.W., and Byrn S.R. Drug Discov. Today 8 (2003) 898-905
2. Kato Y., and Kohket M. Chem. Pharm. Bull. 29 (1981) 268-272
3. Kimura N., Fukui H., Takagaki H., Yonemochi E., and Terada K. Chem. Pharm. Bull. 49 (2001) 1321-1325
4. Miyazaki S., Arita T., Hori R., and Ito K. Chem. Pharm. Bull. 22 (1974) 638-642
5. Rodriguez-Sponga B., Priceb C.P., Jayasankara A., Matzgerb A.J., and Rodriguez-Hornedoa N. Adv. Drug Deliv. Rev. 56 (2004) 241-274
6. Byrn S.R. J. Pharm. Sci. 65 (1976) 1-22
7. Florey K. Analytical Profiles of Drug Substances vol. 17 (1988), Academic Press, New Jersey pp. 1-39
8. Tonnesen H.H. The Photostability of Drugs and Drug Formulations. 2nd ed. (2004), Taylor & Francis, London pp. 354-355
9. Byrn S.R., Xub W., and Newman A.W. Adv. Drug Deliv. Rev. 48 (2001) 115-136
10. Koradia V., Chawla G., and Bansal A.K. Acta Pharm. 54 (2004) 193-204
11. B.B. Lohray, V.B. Lohray, B. Pande, M.G. Dave, Nixon & Vanderhye, Patent US 0,037,842 (2007).
12. P.B. Reddy, K. Reddy, R.R. Reddy, M.D. Reddy, Hetero drugs limited, Patent US 0,100,231 A1 (2006).
13. D. Rao, Cipla Limited, Patent WO 026879 A1 (2004).
14. Mitakos A., and Panderi I. J. Pharm. Biomed. Anal. 28 (2002) 431-438
15. Mohan A., Hariharan M., Vikraman E., Subbaiah G., Venkataraman B.R., and Saravanan D. J. Pharm. Biomed. Anal. 47 (2008) 183-189
16. Agrawal H., Kaul N., Paradkar A.R., and Mahadik K.R. Talanta 61 (2003) 581-589
17. Zaazaa H.E., Abbas S.S., Abdelkawy M., and Abdelrahman M.M. Talanta 78 (2009) 874-884
18. Serajuddin T.M., Thakur A.B., Ghoshal R.N., Fakes M.G., Ranadive S.A., Morris K.R., and Varia S.A. J. Pharm. Sci. 88 (1999) 696-704
19. R. Lifshitz, E. Kovalevski-Ishai, S. Wizel, S.A. Maydan, R. Lidor-hadas, Teva Pharmaceutical Industries Ltd., Patent US 6,767,913 B2 (2004).
20. R. Lifshitz-Liron, E. Kovalevski, S. Wizel, S. Avhar-Maydan, R. Lidor-Hadas, Teva Pharmaceutical Industries Ltd., Patent US 7,074,928 B2 (2006).
21. Danikiewiczl W., and Swist M. J. Mass Spectrom. 42 (2007) 405-406
22. United States Pharmacopeia, 29th ed., The United States Pharmacopeial Convention, Rockville, Maryland, USA, 2006, p. 562.
23. Singh S.S., Sharma K., Barot D., Mohan P.R., and Lohray V.B. J. Chromatogr. B 821 (2005) 173-180
24. Singh S., Bhutani H., Mariappan T.T., Kaur H., Bajaj M., and Pakhale S.P. Int. J. Pharm. 245 (2002) 37-44